PTK2 and carcinoma: To date, most evidence suggests that FAK overexpression and FAK phosphorylation are markers for invasive and metastatic tumors, including carcinomas of the gastrointestinal tract, colon, thyroid, ovary, prostate and oral cavity [17–18, 34–36].